Northern Ontario School of Medicine   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3
Founded: Sudbury; Thunder Bay Canada (2005)

Organization Overview

First Clinical Trial
2005
NCT00401089
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Douglas Boreham | Northern Ontario School of Medicine | Northern Ontario School of Medicine, Thunder Bay Regional Research Institute | Sault Area Hospital | Thunder Bay Regional Health Sciences Centre | Thunder Bay Regional Research Institute

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alzheimer Disease (Phase 1)

Asbestosis (Phase 1)

Bronchiectasis (Phase 1)

Cystic Fibrosis (Phase 1)

Dyskinesias (Phase 2)

Embolism (Phase 1)

Emphysema (Phase 1)

Fibrosis (Phase 1)

Fractures, Bone (Phase 3)

Hip Fractures (Phase 3)

Hypertension, Pulmonary (Phase 1)

Insulin Resistance (Phase 2)

Leiomyoma (Phase 3)

Lung Diseases (Phase 1)

Lung Diseases, Interstitial (Phase 1)

Lung Diseases, Obstructive (Phase 1)

Mesothelioma (Phase 1)

Myofibroma (Phase 3)

Psychotic Disorders (Phase 2)

Pulmonary Disease, Chronic Obstructive (Phase 1)

Pulmonary Embolism (Phase 1)

Pulmonary Fibrosis (Phase 1)

Schizophrenia (Phase 2)

Sleep Apnea, Obstructive (Phase 1)

Tardive Dyskinesia (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 7
  • # of Trial APIs: 10